Phase 2, Multicenter Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Patients With Subarachnoid Hemorrhage Undergoing Endovascular Repair of Ruptured Intracranial Aneurysms
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2015
Price : $35 *
At a glance
- Drugs Nerinetide (Primary)
- Indications Intracranial aneurysm; Subarachnoid haemorrhage
- Focus Therapeutic Use
- Acronyms ENACT-2
- Sponsors NoNO
- 03 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 31 Mar 2015 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020, according to to ClinicalTrials.gov record.
- 31 Mar 2015 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019, according to to ClinicalTrials.gov record.